NovoCure (NVCR) Tax Provisions (2014 - 2026)

NovoCure has disclosed Tax Provisions across 13 years of filings, most recently posting $1.9 million for Q1 2026.

• Tax Provisions for Q1 2026 came in at $1.9 million, down 53.28% year-over-year; the trailing twelve-month figure through Mar 2026 was -$2.2 million (down 106.3% YoY), and the FY2025 annual result was -$23000.0, down 100.06% from the prior year.
• Tax Provisions came in at $1.9 million for Q1 2026 at NovoCure, up from -$16.5 million in the prior quarter.
• In the past five years, Tax Provisions ranged from a high of $10.7 million in Q4 2024 to a low of -$16.5 million in Q4 2025.
• The 5-year median for Tax Provisions is $4.0 million (2025), against an average of $3.8 million.
• Across the five-year window, Tax Provisions jumped 611.4% in 2024 and tumbled 253.56% in 2025, its largest moves.
• NovoCure's Tax Provisions stood at $4.7 million in 2022, then soared by 80.08% to $8.5 million in 2023, then rose by 25.41% to $10.7 million in 2024, then sank by 253.56% to -$16.5 million in 2025, then jumped by 111.43% to $1.9 million in 2026.
• The last three Tax Provisions figures came in at $1.9 million (Q1 2026), -$16.5 million (Q4 2025), and $7.2 million (Q3 2025), per Business Quant data.